Combined effect of bacteria and iron levels on the progression of colorectal cancer

15 Nov 2022
Combined effect of bacteria and iron levels on the progression of colorectal cancer

High levels of certain intestinal bacteria, like Fusobacterium nucleatum, can promote tumour progression in patients with colorectal cancer.

Now, Japanese scientists have revealed a unique mechanism through which excessive iron accumulation accelerates cancer progression in F. nucleatum-positive colorectal cancer.

Their findings show that iron accumulation enhances inflammatory responses in immune cells, promoting tumour growth and contributing to interpatient prognostic variability.

These findings could support the development of new therapeutic strategies and drugs for colorectal cancer.

Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths around the world.

Recent studies have indicated that high levels of intestinal microbes such as Fusobacterium nucleatum in colorectal tumour tissues could lead to a poor prognosis in patients with CRC.

However, factors associated with differences in prognosis among patients with F. nucleatum-positive CRC have so far remained unclear.

As a result, targeted interventions against these tumours have remained limited.

A possible answer could lie in the body’s iron levels, which often determine how the immune system responds to infections.

To explore the mechanisms contributing to tumour progression in CRC and identify case-specific signatures, especially in the context of F. nucleatum-positive CRC, researchers from Kumamoto University and Gifu Pharmaceutical University in Japan investigated the relationship between tumour progression and the body’s iron levels in samples of F. nucleatum-positive CRC.

Their study, recently published in the volume 7 of the Journal of Clinical Investigation (JCI) Insight, revealed that excessive iron accumulation accelerates tumour progression in F. nucleatum-positive colorectal cancer.

“Focusing on the fact that CRC patients with high systemic iron levels show poor survival rates, we clarified the mechanism through which excess iron accelerates the progression of cancer,” says Kumamoto University’s Prof. Toshiro Moroishi, who led the study along with his university colleagues Prof. Hideo Baba, Prof. Tomohiro Sawa, and Prof. Yoshihiro Komohara.

A healthy adult body contains about 3–5 g of iron, equivalent to the amount of iron present in an iron nail.

While iron deficiency causes diseases such as anaemia, excess iron has often been associated with diseases such as cancer.

The researchers were inspired by their previous findings, which revealed that a disruption of iron homeostasis can alter tissue functions in the body.

Hence, to uncover the link between iron levels and CRC prognosis, they analysed tumour tissue specimens from 204 patients diagnosed with stage I, II, or III F. nucleatum-positive or F. nucleatum-negative CRC.

Simultaneously, the iron levels in the tumour tissues were also examined, along with the patients’ serum levels of “transferrin saturation” — an indicator of systemic iron status.

This first round of experiments revealed that both high levels of transferrin saturation and iron deposits within the tumour were associated with a worse overall survival (OS) in patients with F. nucleatum-positive CRC.

The rest of their study was geared towards understanding how iron affects CRC prognosis.

One common link between iron metabolism and cancer progression is the modulation of immune responses, which are mediated by immune cells called macrophages that can both promote and inhibit tumours based on their molecular expression profiles.

Hence, the researchers examined the effect of iron and F. nucleatum levels on the molecular expression profiles of macrophages using RNA sequencing.

They performed in vitro tests in cultured cells and found that F. nucleatum infection can activate the pro-tumour TLR4/NF-κB signalling pathway in macrophages, thus increasing the production of CCL8 — a protein that promotes tumour growth and progression.

Together, the results showed that in F. nucleatum-positive CRC, the bacteria transform macrophages into pro-tumour cells expressing CCL8.  

The role of iron in this process, however, remained unclear.

To find the final piece of this puzzle, the researchers tested how changes in iron levels affect the increase in CCL8 caused by F. nucleatum.

Explains Prof. Moroishi, “In other words, we asked if F. nucleatum can still induce CCL8 expression in macrophages if iron is absent.”

Interestingly, the answer was that it couldn’t.

When iron was removed, the production of CCL8 and other pro-tumour signalling molecules in macrophages was reduced considerably, meaning that they could no longer promote tumour development.

This result explained why patients with F. nucleatum-positive CRC and lower levels of iron showed a better prognosis than their counterparts with high iron levels.

“Our research group has clarified that the combination of F. nucleatum infection and high levels of iron in the body accelerates the progression of CRC,” confirms Prof. Moroishi.

“This means that by targeting iron levels, survival rates could potentially be improved in this patient group,” he adds.

His research team intends to continue exploring the dynamics of iron metabolism in the body in the context of cancer.

Their findings are expected to open new avenues of precision-based preventive strategies and customised therapeutic approaches for patients with CRC.

Source: Kumamoto University